Selective killing of cancer cells by cluttering their waste disposal system

March 16, 2020

A team of researchers from the Center for Soft and Living Matter, within the Institute of Basic Science (IBS, South Korea) and affiliated with Ulsan National Institute of Science and Technology (UNIST) has discovered a novel approach to selectively target and kill several types of cancer cells.

Lysosomes are small sacs filled with a large number of enzymes and acid that work to break down and recycle damaged and unwanted cellular components. In other words, they are simultaneously both a cell's waste container and recycling center. Typically, lysosomes get rid of the byproducts of this degradation process by releasing them outside the cell. Releasing the rubbish outside only makes sense. For example, imagine collecting all the rubbish in your house into a bin and then emptying that very same bin right on the floor in the kitchen, making your living conditions miserable. Similarly, puncturing the lysosomes and releasing their toxic contents inside the cell damages cellular components beyond repair which, in extreme cases, can trigger cell death.

Since cancer lysosomes are easier to damage than healthy cells' lysosomes, scientists have been looking into using this strategy as a promising alternative for targeting cancers that are resistant to conventional treatments. However, only a handful of potential therapeutics can target lysosomes, and most of them lack cancer selectivity.

Published in Nature Nanotechnology, this study shows that nanoparticles covered with a mixture of positively [+] and negatively [-] charged molecules can selectively kill cancer cells by targeting their lysosomes. The death of cancer cells results from a remarkable succession of transport and aggregation phenomena, starting with the formation of small nanoparticle clusters at cell surfaces and culminating with the assembly of micron-sized nanoparticle crystals inside the cancer lysosomes. Nanoparticle crystals induce lysosomal swelling, gradual loss of the integrity of lysosomal membranes, and finally cell death.

"In this work, we have harnessed the deregulated waste management system of the cancer cells to act as a "nanoscale assembly line" for constructing high-quality nanoparticle crystals that destroy the very lysosome "reactors" that allowed them to grow in the first place," says Bartosz A. Grzybowski, co-leading author of the study.

The aggregation of mixed-charge nanoparticles is favored by the acidic environment typical of cancer cells. "Non-cancerous cells, however, also internalize mixed-charge nanoparticles, but nanoparticle aggregation is limited. The nanoparticles quickly transit through the recycling routes and are cleared from these cells," explains Kristiana Kandere-Grzybowska, co-leading author of the study.

"Our conclusions are based on a comparison of thirteen different sarcomas, melanoma, breast and lung carcinoma cell lines with four non-cancer cell types," adds the first author of the study, Magdalena Borkowska. "The nanoparticles were effective against all thirteen cancer lines, while not harming non-cancerous cells."

The aggregation of the nanoparticles as they transit through the endolysosomal system of cancer cells is a complex process. The team discovered that nanoparticles with a surface composition of about 80% [+] and 20% [-] ligands show optimal cancer selectivity. The fact that negatively charged ligands are also pH-sensitive seems to be key to cancer selectivity. In the acidic pH, found around cancerous cells and inside the lysosomes, these ligands are protonated and prone to interact with similar ligands on the neighboring nanoparticles, thus promoting their aggregation. The balance between attractive interactions ? the bonds between [-] ligands and strong interactions between nanoparticle cores ? and electrostatic repulsions between [+] ligands on the neighboring particles determine the extent of nanoparticle aggregation. Overall, the interactions between particles, serum proteins and cells' internal environment work in concert to impair cancer lysosomes.

"The nanoparticle clusters may alter the lipid composition of the lysosome membrane, affect its integrity and render it less mechanically robust. Unexpectedly, our team also discovered that some proteins, such as the cell growth signaling molecules mTORC1, are displaced (and thus inhibited) from the surface of nanoparticle-containing cancer lysosomes. This is important because cancer cell growth and division require mTORC1, and nanoparticles are shutting it down only in cancer cells," explains Kandere-Grzybowska.

While single nanoparticles are approximately the same size as an average protein molecule, and thus too small to be seen with most dynamic live-cell microscopy approaches, the crystals composed of several nanoparticles can be observed. The team used a combination of complementary approaches, including dark-field microscopy, confocal reflection microscopy, and TEM, as well as biochemical and computational approaches to assess the full impact of mixed-charge nanoparticles on lysosomal organelles.

This study opens up new research directions. The mixed-charge strategy could be applied to other types of nanoparticles, such as polymer-based particles, dendrimers or iron oxide nanoparticles. Another important step will be testing the effectiveness of mixed-charge nanoparticles against tumors in animal models.

Institute for Basic Science

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to